- Home
- KLRS vs OPRX Comparison
KLRS vs OPRX Comparison
Compare KLRS & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | OPRX |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.1M | 120.1M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | KLRS | OPRX |
|---|---|---|
| Price | $4.44 | $5.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $19.00 | $16.67 |
| AVG Volume (30 Days) | 80.7K | ★ 509.9K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 124.55 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,429,000.00 |
| Revenue This Year | N/A | $3.88 |
| Revenue Next Year | N/A | $8.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.78 |
| 52 Week Low | $2.14 | $4.57 |
| 52 Week High | $11.88 | $22.25 |
Technical Indicators
Market Signals| Indicator | KLRS | OPRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 42.75 |
| Support Level | $4.35 | $4.57 |
| Resistance Level | $5.43 | $7.10 |
| Average True Range (ATR) | 0.37 | 0.33 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 8.85 | 44.69 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.